NCT05475210 2024-03-13
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
Molecular Targeting Technologies, Inc.
Phase 1 Unknown
Molecular Targeting Technologies, Inc.
Provectus Pharmaceuticals
Taizhou Hanzhong biomedical co. LTD
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Molecular Insight Pharmaceuticals, Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.